8UTK

IL-23R minibinder - 23R-B04dslf02IB

8UTK の概要

• エントリーDOI: 10.2210/pdb8utk/pdb
• 分子名称: 23R-B04dslf02IB, 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE, SULFATE ION, ... (5 entities in total)
• 機能のキーワード: computational design, selective inhibitors, il-2 il-17 cytokines de novo protein, de novo protein
• 由来する生物種: synthetic construct
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 13337.96

構造登録者

Bera, A.K.,Berger, S.A.,Kang, A.,Baker, D. (登録日: 2023-10-31, 公開日: 2024-07-10)

• 主引用文献: Berger, S.,Seeger, F.,Yu, T.Y.,Aydin, M.,Yang, H.,Rosenblum, D.,Guenin-Mace, L.,Glassman, C.,Arguinchona, L.,Sniezek, C.,Blackstone, A.,Carter, L.,Ravichandran, R.,Ahlrichs, M.,Murphy, M.,Pultz, I.S.,Kang, A.,Bera, A.K.,Stewart, L.,Garcia, K.C.,Naik, S.,Spangler, J.B.,Beigel, F.,Siebeck, M.,Gropp, R.,Baker, D.; Preclinical proof of principle for orally delivered Th17 antagonist miniproteins.; Cell, 2024; PubMed: 38936360; DOI: 10.1016/j.cell.2024.05.052

実験手法

X-RAY DIFFRACTION (1.94 Å)